Evidence Based Medicine (EBM)

Evidence based medicine (EBM) is the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients.^[3] It integrates three components: the best available external clinical evidence from systematic research, the clinician's individual expertise and judgment, and the patient's values, preferences, and circumstances.^[3][5] EBM does not mean making decisions based on evidence alone; it means combining evidence with clinical experience and patient preferences to identify the course of action most likely to benefit each individual patient.

Before the EBM movement, medical practice was guided largely by tradition, authority, unsystematic clinical experience, and pathophysiological reasoning. These sources, while valuable, are unreliable when used in isolation.^[4] Authority based medicine led to the perpetuation of treatments that were ineffective or harmful, such as bed rest for back pain and routine episiotomy in childbirth, long after evidence had accumulated against them. EBM provides a framework for critically appraising and applying research evidence to clinical decisions, reducing the influence of bias and tradition and improving patient outcomes. Since Gordon Guyatt coined the term in 1991 and the Evidence-Based Medicine Working Group, which included David Sackett, set out the approach in JAMA in 1992, EBM has transformed medical education, clinical practice, guideline development, and health policy worldwide.^[4][5] The core wording of the definition above, "the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients", comes from Sackett and colleagues, writing in the BMJ in 1996.^[3]

Fourth, the appraised evidence is integrated with clinical expertise and the patient's values and circumstances to make a decision. Clinical expertise includes the clinician's knowledge of the disease, the local healthcare context, and the practical feasibility of different options. Patient values include preferences about outcomes (some patients prioritize longevity, others prioritize quality of life), risk tolerance, and practical considerations (cost, convenience, family circumstances). Fifth, the clinician evaluates the outcome of the decision and the process, seeking to improve future practice.

The hierarchy of evidence provides a framework for ranking the strength of different types of research. Systematic reviews and meta analyses of randomized controlled trials are considered the highest level of evidence for questions about treatment effectiveness. Individual RCTs, cohort studies, case control studies, case series, and expert opinion are progressively lower levels. However, the hierarchy is not rigid; a well conducted observational study may provide stronger evidence than a poorly conducted RCT, and for questions about prognosis, etiology, or diagnosis, different study designs may be most appropriate.^[3][5]

EBM has evolved to encompass not only individual clinical decision making but also the development of clinical practice guidelines, health technology assessments, and quality improvement initiatives. The GRADE system provides a structured approach to rating the certainty of evidence and formulating recommendations. It rates certainty for each outcome rather than by study design alone: a body of randomized evidence starts high and observational evidence starts low, and either can be rated down (for example for risk of bias, inconsistency or imprecision) or, for observational evidence, rated up (for example for a large effect).^[1][2] Many organizations worldwide, including the World Health Organization and Cochrane, have adopted GRADE.^[1]

EBM principles should guide clinical decision making in every patient encounter, though the depth of evidence searching and appraisal will vary depending on the clinical situation. For common clinical questions, pre appraised evidence summaries and clinical guidelines provide efficient access to current best evidence. For unusual or complex cases, a more thorough search and critical appraisal may be necessary. EBM is not limited to treatment decisions; it applies to diagnostic testing, screening, prevention, prognosis, and harm assessment. It is not appropriate to rigidly apply evidence from trials to patients who would not have been eligible for those trials without considering the differences; clinical expertise and patient values serve as essential modifiers of the evidence.

A 72 year old woman with newly diagnosed atrial fibrillation asks her cardiologist about stroke prevention. Applying EBM, the cardiologist formulates the question: "In elderly women with atrial fibrillation, do direct oral anticoagulants reduce stroke risk compared to warfarin?" A search identifies a meta analysis of the four large trials comparing DOACs with warfarin, showing that DOACs reduced stroke or systemic embolism by 19% relative to warfarin (risk ratio 0.81), with a lower risk of intracranial hemorrhage but a higher risk of gastrointestinal bleeding. Appraising the evidence, the cardiologist notes that the meta analysis included patients over 70 but that the patient's kidney function (mild impairment) needs checking against each drug's dosing criteria, and her fall risk needs weighing against the bleeding risks. After discussing the options, including the patient's preference for avoiding regular blood tests (required with warfarin), they jointly decide on a DOAC, dosed according to her kidney function, with regular renal monitoring.